Literature DB >> 24806289

Erythropoietin responsive cardiomyogenic cells contribute to heart repair post myocardial infarction.

Maria Patapia Zafiriou1, Claudia Noack, Bernhard Unsöld, Michael Didie, Elena Pavlova, Henrike J Fischer, Holger M Reichardt, Martin W Bergmann, Ali El-Armouche, Wolfram-Hubertus Zimmermann, Laura Cecilia Zelarayan.   

Abstract

The role of erythropoietin (Epo) in myocardial repair after infarction remains inconclusive. We observed high Epo receptor (EPOR) expression in cardiac progenitor cells (CPCs). Therefore, we aimed to characterize these cells and elucidate their contribution to myocardial regeneration on Epo stimulation. High EPOR expression was detected during murine embryonic heart development followed by a marked decrease until adulthood. EPOR-positive cells in the adult heart were identified in a CPC-enriched cell population and showed coexpression of stem, mesenchymal, endothelial, and cardiomyogenic cell markers. We focused on the population coexpressing early (TBX5, NKX2.5) and definitive (myosin heavy chain [MHC], cardiac Troponin T [cTNT]) cardiomyocyte markers. Epo increased their proliferation and thus were designated as Epo-responsive MHC expressing cells (EMCs). In vitro, EMCs proliferated and partially differentiated toward cardiomyocyte-like cells. Repetitive Epo administration in mice with myocardial infarction (cumulative dose 4 IU/g) resulted in an increase in cardiac EMCs and cTNT-positive cells in the infarcted area. This was further accompanied by a significant preservation of cardiac function when compared with control mice. Our study characterized an EPO-responsive MHC-expressing cell population in the adult heart. Repetitive, moderate-dose Epo treatment enhanced the proliferation of EMCs resulting in preservation of post-ischemic cardiac function.
© 2014 AlphaMed Press.

Entities:  

Keywords:  Epo-responsive MHC expressing cells; Erythropoietin; Erythropoietin responsive myosin heavy chain expressing cells; Ischemia; Myocardial regeneration

Mesh:

Substances:

Year:  2014        PMID: 24806289     DOI: 10.1002/stem.1741

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  12 in total

Review 1.  Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.

Authors:  Rosalinda Madonna; Linda W Van Laake; Sean M Davidson; Felix B Engel; Derek J Hausenloy; Sandrine Lecour; Jonathan Leor; Cinzia Perrino; Rainer Schulz; Kirsti Ytrehus; Ulf Landmesser; Christine L Mummery; Stefan Janssens; James Willerson; Thomas Eschenhagen; Péter Ferdinandy; Joost P G Sluijter
Journal:  Eur Heart J       Date:  2016-04-07       Impact factor: 29.983

Review 2.  Erythropoietin and the use of a transgenic model of erythropoietin-deficient mice.

Authors:  Aurélien Pichon; Florine Jeton; Raja El Hasnaoui-Saadani; Luciana Hagström; Thierry Launay; Michèle Beaudry; Dominique Marchant; Patricia Quidu; Jose-Luis Macarlupu; Fabrice Favret; Jean-Paul Richalet; Nicolas Voituron
Journal:  Hypoxia (Auckl)       Date:  2016-04-07

Review 3.  Global position paper on cardiovascular regenerative medicine.

Authors:  Francisco Fernández-Avilés; Ricardo Sanz-Ruiz; Andreu M Climent; Lina Badimon; Roberto Bolli; Dominique Charron; Valentin Fuster; Stefan Janssens; Jens Kastrup; Hyo-Soo Kim; Thomas F Lüscher; John F Martin; Philippe Menasché; Robert D Simari; Gregg W Stone; Andre Terzic; James T Willerson; Joseph C Wu
Journal:  Eur Heart J       Date:  2017-09-01       Impact factor: 29.983

Review 4.  Translational cardiac stem cell therapy: advancing from first-generation to next-generation cell types.

Authors:  Elena Cambria; Francesco S Pasqualini; Petra Wolint; Julia Günter; Julia Steiger; Annina Bopp; Simon P Hoerstrup; Maximilian Y Emmert
Journal:  NPJ Regen Med       Date:  2017-06-13

5.  Cathepsin A contributes to left ventricular remodeling by degrading extracellular superoxide dismutase in mice.

Authors:  Mathias Hohl; Manuel Mayr; Lisa Lang; Alexander G Nickel; Javier Barallobre-Barreiro; Xiaoke Yin; Thimoteus Speer; Simina-Ramona Selejan; Claudia Goettsch; Katharina Erb; Claudia Fecher-Trost; Jan-Christian Reil; Benedikt Linz; Sven Ruf; Thomas Hübschle; Christoph Maack; Michael Böhm; Thorsten Sadowski; Dominik Linz
Journal:  J Biol Chem       Date:  2020-07-09       Impact factor: 5.157

6.  Suppression of Inflammatory Cardiac Cytokine Network in Rats with Untreated Obesity and Pre-Diabetes by AT2 Receptor Agonist NP-6A4.

Authors:  Madhavi P Gavini; Abuzar Mahmood; Anthony M Belenchia; Paige Beauparlant; Senthil A Kumar; Sivakumar Ardhanari; Vincent G DeMarco; Lakshmi Pulakat
Journal:  Front Pharmacol       Date:  2021-06-18       Impact factor: 5.810

7.  Erythropoietin stimulates the coronary collateral development in patients with coronary chronic total occlusion.

Authors:  I O Yuksel; G Cagirci; E Koklu; A Yilmaz; S Kucukseymen; H Y Ellidag; S Cay; N Yilmaz; S Arslan
Journal:  Neth Heart J       Date:  2016-10       Impact factor: 2.380

Review 8.  Alternative Erythropoietin Receptors in the Nervous System.

Authors:  Daniela Ostrowski; Ralf Heinrich
Journal:  J Clin Med       Date:  2018-02-02       Impact factor: 4.241

9.  Preclinical evidence for the therapeutic value of TBX5 normalization in arrhythmia control.

Authors:  Franziska S Rathjens; Alica Blenkle; Lavanya M Iyer; Anke Renger; Fahima Syeda; Claudia Noack; Andreas Jungmann; Matthias Dewenter; Karl Toischer; Ali El-Armouche; Oliver J Müller; Larissa Fabritz; Wolfram-Hubertus Zimmermann; Laura C Zelarayan; Maria-Patapia Zafeiriou
Journal:  Cardiovasc Res       Date:  2021-07-07       Impact factor: 10.787

Review 10.  Erythropoietin Receptor/β Common Receptor: A Shining Light on Acute Kidney Injury Induced by Ischemia-Reperfusion.

Authors:  Yuanyuan Wu; Bin Yang
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.